Agency Information Collection Activities: Submission for OMB Review; Comment Request, 37912 [2012-15414]
Download as PDF
<![CDATA[
37912
Federal Register / Vol. 77, No. 122 / Monday, June 25, 2012 / Notices
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Phase II Trials in Lung Disease.
Date: July 12, 2012.
Time: 8:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Renaissance Washington DC,
Dupont Circle, 1143 New Hampshire Avenue
NW., Washington, DC 20037.
Contact Person: Stephanie L Constant,
Ph.D., Scientific Review Officer, Office of
Scientific Review/DERA, National Heart,
Lung, and Blood Institute, 6701 Rockledge
Drive, Room 7189, Bethesda, MD 20892, 301–
443–8784, constantsl@nhlbi.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: June 14, 2012.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–15472 Filed 6–22–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–1243.
Project: Enhancing Substance Abuse
Treatment Services To Address
Hepatitis Infection Among Intravenous
Drug Users Hepatitis Testing and
Vaccine Tracking Form (OMB No.
0930–0300)—Reinstatement and
Extension
The Substance Abuse and Mental
Health Services Administration’s
(SAMHSA) Center Substance Abuse
Treatment (CSAT), is responsible for the
Hepatitis Testing and Vaccine Tracking
Form for the prevention of Viral
Hepatitis in patients in designated
Opioid Treatment Programs (OTPs).
There are no changes to the form or
added burden.
This form allows SAMHSA/CSAT to
collect essential Clinical information
that will be used for quality assurance,
quality performance and product
monitoring on approximately 264 Rapid
Hepatitis C Test kits and 10,628 doses
of hepatitis vaccine (Twinrix, HAV, or
HBV). The above kits and vaccines will
be provided to designated OTPs serving
the minority population in their
communities. The information collected
on the Form solicits and reflect the
following information:
• Demographics (age, gender, ethnicity)
of designated OTP site
• History (Screening) of Hepatitis C
exposure
• Results of Rapid Hepatitis C Testing
(Kit) and Follow-up information
• Service Provided (type of vaccine
given) Divalent vaccine (Twinrixcombination HAV and HBV) or
Monovalent vaccine (HAV and/or
HBV)
• Substance Abuse Treatment
Outcomes (Information regarding the
beginning, continuing or completion
of vaccination series)
• Type of Referral Services Indicated
(i.e., Gastroenterology, TB; Mental
Health, Counseling, Reproductive/
Prenatal, etc.)
This program is authorized under
Section 509 of the Public Health Service
(PHS) Act [42 U.S.C. 290bb–2].
The form increases the screening and
reporting of viral hepatitis in high risk
minorities in OTPs. The information
collected allows SAMHSA to address
the increased morbidity and mortality of
hepatitis in minorities being treated for
drug addiction.
The SAMHSA/CSAT Hepatitis
Testing and Vaccine Tracking Form
supports quality of care, provide
minimum but adequate clinical and
product monitoring, and provide
appropriate safeguards against fraud,
waste and abuse of Federal funds.
The table below reflects the
annualized hourly burden.
Responses/
respondent
Burden hours
Total burden hours
50,000
erowe on DSK2VPTVN1PROD with NOTICES
Number of
respondents
screened
1
0.05
2,500
Written comments and
recommendations concerning the
proposed information collection should
be sent by July 25, 2012 to the SAMHSA
Desk Officer at the Office of Information
and Regulatory Affairs, Office of
Management and Budget (OMB). To
ensure timely receipt of comments, and
to avoid potential delays in OMB’s
receipt and processing of mail sent
through the U.S. Postal Service,
commenters are encouraged to submit
their comments to OMB via email to:
OIRA_Submission@omb.eop.gov.
Although commenters are encouraged to
send their comments via email,
commenters may also fax their
comments to: 202–395–7285.
VerDate Mar<15>2010
14:55 Jun 22, 2012
Jkt 226001
Commenters may also mail them to:
Office of Management and Budget,
Office of Information and Regulatory
Affairs, New Executive Office Building,
Room 10102, Washington, DC 20503.
[Docket No. DHS–2012–0026]
Committee Name: Homeland Security
Academic Advisory Council
Summer King,
Statistician.
[FR Doc. 2012–15414 Filed 6–22–12; 8:45 am]
BILLING CODE 4162–20–P
PO 00000
DEPARTMENT OF HOMELAND
SECURITY
Department of Homeland
Security.
AGENCY:
Committee Management; Notice
of Federal Advisory Committee Meeting.
ACTION:
The Homeland Security
Academic Advisory Council (HSAAC)
will meet on July 10, 2012 in
Washington, DC. The meeting will be
open to the public.
SUMMARY:
Frm 00044
Fmt 4703
Sfmt 4703
E:\FR\FM\25JNN1.SGM
25JNN1
]]>Agencies
[Federal Register Volume 77, Number 122 (Monday, June 25, 2012)]
[Notices]
[Page 37912]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-15414]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Agency Information Collection Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and Mental Health Services
Administration (SAMHSA) will publish a summary of information
collection requests under OMB review, in compliance with the Paperwork
Reduction Act (44 U.S.C. Chapter 35). To request a copy of these
documents, call the SAMHSA Reports Clearance Officer on (240) 276-1243.
Project: Enhancing Substance Abuse Treatment Services To Address
Hepatitis Infection Among Intravenous Drug Users Hepatitis Testing and
Vaccine Tracking Form (OMB No. 0930-0300)--Reinstatement and Extension
The Substance Abuse and Mental Health Services Administration's
(SAMHSA) Center Substance Abuse Treatment (CSAT), is responsible for
the Hepatitis Testing and Vaccine Tracking Form for the prevention of
Viral Hepatitis in patients in designated Opioid Treatment Programs
(OTPs). There are no changes to the form or added burden.
This form allows SAMHSA/CSAT to collect essential Clinical
information that will be used for quality assurance, quality
performance and product monitoring on approximately 264 Rapid Hepatitis
C Test kits and 10,628 doses of hepatitis vaccine (Twinrix, HAV, or
HBV). The above kits and vaccines will be provided to designated OTPs
serving the minority population in their communities. The information
collected on the Form solicits and reflect the following information:
Demographics (age, gender, ethnicity) of designated OTP site
History (Screening) of Hepatitis C exposure
Results of Rapid Hepatitis C Testing (Kit) and Follow-up
information
Service Provided (type of vaccine given) Divalent vaccine
(Twinrix- combination HAV and HBV) or Monovalent vaccine (HAV and/or
HBV)
Substance Abuse Treatment Outcomes (Information regarding the
beginning, continuing or completion of vaccination series)
Type of Referral Services Indicated (i.e., Gastroenterology,
TB; Mental Health, Counseling, Reproductive/Prenatal, etc.)
This program is authorized under Section 509 of the Public Health
Service (PHS) Act [42 U.S.C. 290bb-2].
The form increases the screening and reporting of viral hepatitis
in high risk minorities in OTPs. The information collected allows
SAMHSA to address the increased morbidity and mortality of hepatitis in
minorities being treated for drug addiction.
The SAMHSA/CSAT Hepatitis Testing and Vaccine Tracking Form
supports quality of care, provide minimum but adequate clinical and
product monitoring, and provide appropriate safeguards against fraud,
waste and abuse of Federal funds.
The table below reflects the annualized hourly burden.
----------------------------------------------------------------------------------------------------------------
Number of respondents
screened Responses/ respondent Burden hours Total burden hours
----------------------------------------------------------------------------------------------------------------
50,000 1 0.05 2,500
----------------------------------------------------------------------------------------------------------------
Written comments and recommendations concerning the proposed
information collection should be sent by July 25, 2012 to the SAMHSA
Desk Officer at the Office of Information and Regulatory Affairs,
Office of Management and Budget (OMB). To ensure timely receipt of
comments, and to avoid potential delays in OMB's receipt and processing
of mail sent through the U.S. Postal Service, commenters are encouraged
to submit their comments to OMB via email to: OIRA_Submission@omb.eop.gov. Although commenters are encouraged to send
their comments via email, commenters may also fax their comments to:
202-395-7285. Commenters may also mail them to: Office of Management
and Budget, Office of Information and Regulatory Affairs, New Executive
Office Building, Room 10102, Washington, DC 20503.
Summer King,
Statistician.
[FR Doc. 2012-15414 Filed 6-22-12; 8:45 am]
BILLING CODE 4162-20-P
